Trials / Completed
CompletedNCT00736775
A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease
A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous MABT5102A Administered in a Single-Dose, Dose-Escalation Stage Followed by a Multidose, Parallel-Treatment Stage in Patients With Mild to Moderate Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 50 Years – 86 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I, multicenter, randomized, double-blind, placebo-controlled study that will be conducted in the United States and consists of a single ascending-dose stage followed by a multidose, parallel-treatment stage. This study will be conducted in approximately 50 adult patients between 50-85 years old who have mild to moderate Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | anti-Abeta | Intravenous single and multiple doses |
| DRUG | placebo | Intravenous single and multiple doses |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2010-05-01
- First posted
- 2008-08-18
- Last updated
- 2010-10-27
Source: ClinicalTrials.gov record NCT00736775. Inclusion in this directory is not an endorsement.